The therapeutic potential of targeting HDAC6 with Tubastatin A in TFK-1 and EGI-1 cholangiocarcinoma cells

Münevver Yenigül; Emel Gencer Akcok

EN

The therapeutic potential of targeting HDAC6 with Tubastatin A in TFK-1 and EGI-1 cholangiocarcinoma cells

Abstract

Cholangiocarcinoma (CCA) is a highly aggressive and invasive malignancy with a poor diagnosis because of the resistance, relapse and limited therapy. Histone deacetylases (HDAC) are a class of enzyme that have important roles in epigenetic modulations. These enzymes are intensely studied and HDAC inhibitors are considered as potent anticancer agents in both solid tumors and hematological malignancies. HDAC inhibitors can affect and induce different mechanisms such as cell cycle arrest, differentiation, and cell death. In this study, we aim to investigate the cytotoxic effect of Tubastatin A, which is a selective HDAC6 inhibitor, on cholangiocarcinoma cell lines, TFK-1 and EGI-1, by MTT assay. Besides, it was aimed to examine the impact on colony formation potential of the cells. The effect of the inhibitor on cell cycle distribution was also examined by using flow cytometry. Tubastatin A has significantly decreased the colony formation and changed cell cycle progression. Taken together, our results suggest that Tubastatin A could be a potent inhibitor against cholangiocarcinoma. On the basis of these results, further mechanistic studies are required to elucidate the antineoplastic activity of Tubastatin A.

Keywords

Cholangiocarcinoma, Histonedeacetylase, Tubastatin A, HDAC inhibitors, HDAC6.

Project Number

217S660

References

[1] Pant K., Peixoto E., Richard S. Gradilone, S. A., Role of Histone Deacetylases in Carcinogenesis: Potential Role in Cholangiocarcinoma, Cells, 9(3) (2020) 780.
[2] Rizvi S., Gores G. J., Pathogenesis, diagnosis, and management of cholangiocarcinoma, Gastroenterology, 145(6) (2013) 1215-29.
[3] Dawson M. A., Kouzarides T., Cancer epigenetics: From mechanism to therapy, Cell, 150(1) (2012) 12-27.
[4] Weinhold B., Epigenetics: the science of change, Environ. Health Perspect., 114(3) (2006) 160-7.
[5] Li Y., Seto E., HDACs and HDAC inhibitors in cancer development and therapy, Cold Spring Harb. Perspect. Med., 6(10) (2016) a026831.
[6] Sriraks R., Limpaiboon T., Histone deacetylases and their inhibitors as potential therapeutic drugs for cholangiocarcinoma–cell line findings, Asian Pacific J. Cancer Prev., 14(4) (2013) 2503-2508.
[7] Dokmanovic M., Clarke C., Marks P. A., Histone deacetylase inhibitors: Overview and perspectives, Molecular Cancer Research, 5(10) (2007) 981-989.
[8] Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., Yoshida M., Wang X. F., Yao T. P., HDAC6 is a microtubuleassociated deacetylase, Nature, 417(6887) (2002) 455-458.
[9] Sakamoto K. M., Aldana-Masangkay G. I., The role of HDAC6 in cancer, Journal of Biomedicine and Biotechnology, 2011 (2011) 875824.
[10] Gradilone S. A., Pisarello M. J., LaRusso N. F., Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma, Curr. Drug Targets, 18(8) (2015) 958-963.

[11] Gradilone S. A., Radtke B. N., Bogert P. S., Huang B. Q., Gajdos G. B., LaRusso N. F., HDAC6 inhibition restores ciliary expression and decreases tumor growth, Cancer Res., 73(7) (2013) 2259-2270.
[12] Gradilone S. A., Gradilone S. A., Habringer S., Masyuk T. V., Howard B. N., Masyuk A. I., Larusso N. F., HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis, Am. J. Pathol, 184(3) (2014) 600–608.
[13] Urdiciain A., Erausquin E., Meléndez B., Rey J. A., Idoate M. A., Castresana J. S., Tubastatin A, an inhibitor of HDAC6, enhances temozolomide-induced apoptosis and reverses the malignant phenotype of glioblastoma cells, Int. J. Oncol, 54(5) (2019) 1797-1808.
[14] Marks D. C., Belov L., Davey M. W., Davey R. A., Kidman A. D., The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells, Leuk. Res., 16(12) (1992) 1165-1173.
[15] Rizvi S., Khan S. A., Hallemeier C. L., Kelley R. K., Gores G. J., Cholangiocarcinoma-evolving concepts and therapeutic strategies, Nature Reviews Clinical Oncology, 15(2) (2018) 95-111.
[16] Valle J., Wasan H., Palmer D. H., Cunningham D., Anthoney A., Maraveyas A., Madhusudan S., Iveson T., Hughes S., Pereira S. P., Roughton M., Bridgewater J., ABC-02 Trial Investigators., Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer, N. Engl. J. Med., 362(14) (2010) 1273-81.
[17] Eberharter A., Becker P. B., Histone acetylation: A switch between repressive and permissive chromatin. Second in review on chromatin dynamics, EMBO Rep., 3(3) (2002) 224-9.
[18] Egger G., Liang G., Aparicio A., Jones P. A., Epigenetics in human disease and prospects for epigenetic therapy, Nature, 429(6990) (2004) 457-63.
[19] Cheng Y., He C., Wang M., Ma X., Mo F., Yang S., Han J., Wei X., Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials, Signal Transduct. Target. Ther., 4 (2019) 62.
[20] Bates S. E., Epigenetic Therapies for Cancer, N. Engl. J. Med., 383(7) (2020) 650-663.
[21] Dong J., Zheng N., Wang X., Tang C., Yan P., Zhou H. B., Huang J., A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer, Eur. J. Pharmacol., 828 (2018) 67-79.
[22] Wang G., He J., Zhao J., Yun W., Xie C., Taub J. W., Azmi A., Mohammad R. M., Dong Y., Kong W., Guo Y., Ge Y., Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer, PLoS One, 7(12) (2012) e52095.
[23] Won H. R., Ryu H. W., Shin D. H., Yeon S. K., Lee D. H., Kwon S.H., A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells, Mol. Carcinog., 57(10) (2018) 1383- 1395.
[24] Su Y., Hopfinger N. R., Nguyen T. D., Pogash T. J., Santucci-Pereira J., Russo J., Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors, J. Exp. Clin. Cancer Res., 37(1) (2018) 314.
[25] Li Y., Shin D., Kwon S. H., Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes, FEBS Journal, 280(3) (2013) 775-93.
[26] Woan K. V., Lienlaf M., Perez-Villaroel P., Lee C., Cheng F., Knox T., Woods D. M., Barrios K., Powers J., Sahakian E., Wang H. W., Canales J., Marante D., Smalley K. S. M., Bergman J., Seto E., Kozikowski A., Pinilla-Ibarz J., Sarnaik A., Celis E., Weber J., Sotomayor E. M., Villagra A., Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation, Mol. Oncol., 9(7) (2015) 1447–1457.

Details

Primary Language

English

Subjects

Structural Biology

Journal Section

Research Article

Authors

Münevver Yenigül This is me
0000-0003-0468-721X
Türkiye

Emel Gencer Akcok ^*
0000-0002-6559-9144
Türkiye

Publication Date

December 29, 2021

Submission Date

July 6, 2021

Acceptance Date

December 12, 2021

Published in Issue

Year 2021 Volume: 42 Number: 4

IZ

https://izlik.org/JA98JK29KC

APA

Yenigül, M., & Gencer Akcok, E. (2021). The therapeutic potential of targeting HDAC6 with Tubastatin A in TFK-1 and EGI-1 cholangiocarcinoma cells. Cumhuriyet Science Journal, 42(4), 775-780. https://izlik.org/JA98JK29KC

AMA

1.Yenigül M, Gencer Akcok E. The therapeutic potential of targeting HDAC6 with Tubastatin A in TFK-1 and EGI-1 cholangiocarcinoma cells. CSJ. 2021;42(4):775-780. https://izlik.org/JA98JK29KC

Chicago

Yenigül, Münevver, and Emel Gencer Akcok. 2021. “The Therapeutic Potential of Targeting HDAC6 With Tubastatin A in TFK-1 and EGI-1 Cholangiocarcinoma Cells”. Cumhuriyet Science Journal 42 (4): 775-80. https://izlik.org/JA98JK29KC.

EndNote

Yenigül M, Gencer Akcok E (December 1, 2021) The therapeutic potential of targeting HDAC6 with Tubastatin A in TFK-1 and EGI-1 cholangiocarcinoma cells. Cumhuriyet Science Journal 42 4 775–780.

IEEE

[1]M. Yenigül and E. Gencer Akcok, “The therapeutic potential of targeting HDAC6 with Tubastatin A in TFK-1 and EGI-1 cholangiocarcinoma cells”, CSJ, vol. 42, no. 4, pp. 775–780, Dec. 2021, [Online]. Available: https://izlik.org/JA98JK29KC

ISNAD

Yenigül, Münevver - Gencer Akcok, Emel. “The Therapeutic Potential of Targeting HDAC6 With Tubastatin A in TFK-1 and EGI-1 Cholangiocarcinoma Cells”. Cumhuriyet Science Journal 42/4 (December 1, 2021): 775-780. https://izlik.org/JA98JK29KC.

JAMA

1.Yenigül M, Gencer Akcok E. The therapeutic potential of targeting HDAC6 with Tubastatin A in TFK-1 and EGI-1 cholangiocarcinoma cells. CSJ. 2021;42:775–780.

MLA

Yenigül, Münevver, and Emel Gencer Akcok. “The Therapeutic Potential of Targeting HDAC6 With Tubastatin A in TFK-1 and EGI-1 Cholangiocarcinoma Cells”. Cumhuriyet Science Journal, vol. 42, no. 4, Dec. 2021, pp. 775-80, https://izlik.org/JA98JK29KC.

Vancouver

1.Münevver Yenigül, Emel Gencer Akcok. The therapeutic potential of targeting HDAC6 with Tubastatin A in TFK-1 and EGI-1 cholangiocarcinoma cells. CSJ [Internet]. 2021 Dec. 1;42(4):775-80. Available from: https://izlik.org/JA98JK29KC

As of 2026, Cumhuriyet Science Journal will be published in six issues per year, released in February, April, June, August, October, and December

The therapeutic potential of targeting HDAC6 with Tubastatin A in TFK-1 and EGI-1 cholangiocarcinoma cells

Abstract

Supporting Institution

Project Number

The therapeutic potential of targeting HDAC6 with Tubastatin A in TFK-1 and EGI-1 cholangiocarcinoma cells

Abstract

Keywords

Project Number

References

Details

Primary Language

Subjects

Journal Section

Authors

Publication Date

Submission Date

Acceptance Date

Published in Issue

IZ

Cite